Clinical trials: Graft-vs-host Disease
Chronic Lymphocytic Leukemia, Graft vs Host Disease
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
Cancers of the blood, sometimes referred to as hematologic malignancies, are disorders of bone marrow cells that lead to the failure of the normal function of bone marrow and the uncontrolled growth of cancerous cells in the bone…
- Conditions
- Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hematologic Neoplasm, Multiple Myeloma
- Trial name
- NCT00001873
- Testing
- Isolex 300i plus MoAbs
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Graft Versus Host Disease in Eye, Ocular Complications
Ocular Complications From Cancer Therapy - Patient Registry and Biobank
The purpose of this study is to collect data on patients seen at University of Maryland after undergoing cancer therapy. Previous medications, ocular history, medical history, clinical evaluations, surgical procedures and…
- Conditions
- Graft Versus Host Disease in Eye, Ocular Complications, Inflammatory Dry Eye Disease
- Trial name
- NCT06874283
- Testing
- Eye exam
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Acute Leukemia, Myelodysplastic Syndromes
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
Graft-versus-host disease (GVHD) is an important complication after transplantation, with an incidence of 40-60%, which can increase non-relapse mortality if poorly controlled.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia
- Trial name
- NCT06279494
- Testing
- Sirolimus, Abatacept, MMF
- Volunteers
- 6 people
- Sponsor
- Peking University People's Hospital
Graft vs Host Disease, Graft-Versus-Host Disease
Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD
This protocol allows for the treatment of pediatric patients, male and female, between the ages of 2 months and 17 years. Patients must have failed steroid treatment for Grade B-D acute GVHD.
- Trial name
- NCT00759018
- Testing
- remestemcel-L
- Where
- 27 sites in United States, Canada
- Sponsor
- Mesoblast, Inc.
Ocular Graft vs Host Disease, Dry Eye
rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
The purpose of this study is to evaluate the tolerability and preliminary efficacy of rhDNase I eye drops in patients with ocular Graft-vs.-Host disease (oGVHD).
- Trial name
- NCT02702518
- Testing
- rhDNase I, Vehicle
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Illinois Chicago
Hepatitis B
48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to investigate whether in patients with chronic HBeAg-negative hepatitis B, PEG-IFN-ribavirin combination therapy for 1 year leads to enhanced response (HBV DNA <10E4 copies/ml and normal ALT 24 weeks…
- Trial name
- NCT00114361
- Testing
- Ribavirin, Peginterferon alpha 2a
- Where
- Netherlands
- Volunteers
- 138 people
- Sponsor
- Foundation for Liver Research
GVHD
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
This is a single arm open label phase II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from matched-related or unrelated donor are eligible for the study if they meet the standard…
- Trial name
- NCT03945591
- Testing
- Bortezomib, Cyclophosphamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- NYU Langone Health
Chronic Graft Versus Host Disease Oral
Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD)
This study aims to investigate the use of a novel formulation of tacrolimus, as a toothpaste, in a population of patients with oral chronic graft vs.
- Trial name
- NCT06638879
- Testing
- Tacrolimus
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Graft Versus Host Disease, Leukemia
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00014469
- Testing
- busulfan, melphalan, methotrexate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diagnoses That Require Stem Cell Transplant, Graft Versus Host Disease (GVHD)
Maraviroc as GVHD Prophylaxis in Transplant Recipients
The purpose is to determine if the addition of Maraviroc to a standard transplant regimen will reduce the incidence of graft versus host disease in children and young adults after a stem cell transplant.
- Trial name
- NCT02167451
- Testing
- Maraviroc
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Acute Graft Versus Host Disease
Studying Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid Myopathy
This trial investigates the changes in physical and functional tests over time in patients with suspected acute graft versus host disease (from a hematologic stem cell transplant) who started treatment with corticosteroids.
- Trial name
- NCT04521777
- Testing
- Exercise Intervention, Physical Performance Testing, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Dry Eye Disease
Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST)
A prospective, single-blinded, randomized, controlled crossover trial was conducted in patients with severe dry eye syndrome. Topical treatment with autologous serum eye drops (ASED) diluted at 20%, undiluted ASED and…
- Trial name
- AST (NCT07469865)
- Testing
- Preservative-free artificial tears, Autologous serum eyedrops 20%, Autologous serum eyedrops 100%
- Where
- Belgium
- Volunteers
- 46 people
- Sponsor
- University Hospital, Ghent
Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
MaaT013 is still in clinical development phase and is not approved yet for marketing in any region. During the development program, MaaT Pharma has undertaken initial development with closely related product candidates, leading…
- Trial name
- ATLAS (NCT04768907)
- Testing
- MaaT013
- Where
- 46 sites in Austria, Belgium and 6 more
- Sponsor
- MaaT Pharma
GVHD, Acute
PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT
All patients received Flu-BU-VP16 as myeloablative conditioning followed by cyclophosphamide (D+3 and +4) and subsequent tacrolimus. For patients with unrelated or haplo-donor received low-dose ATG at Day +15.
- Trial name
- NCT04118075
- Testing
- PT-CY-FK +/-ATG
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Graft-versus-host Disease
Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic Transplant
Recent published data suggest that specific alterations in intestinal metabolome signature of hematopoietic stem cell transplant (allo-SCT) recipients might influence incidence and severity of acute graft versus host disease…
- Trial name
- AlloBolome (NCT05186857)
- Where
- 9 sites in Spain
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Graft Vs Host Disease
Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT
This research project delves into the critical role of gut immunity in the occurrence and progression of acute graft-versus-host disease (aGVHD) post allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- NCT06143501
- Testing
- Blood Sample, Stool Sample, Urine Sample
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
AML
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
The goal of this clinical research study is to compare the effects of these drug combinations (cyclophosphamide, sirolimus, and MMF vs cyclophosphamide, sirolimus, and ruxolitinib) on the prevention of GVHD after a stem cell…
- Trial name
- NCT06973668
- Testing
- Mycophenolate Mofetil, Ruxolitinib
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Hematopoietic Stem Cell Transplantation
Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant
The purpose of this study is to determine whether vitamin D is effective in the prevention of graft-versus-host-disease after completion of allogeneic transplant.
- Trial name
- Alovita-1 (NCT02600988)
- Testing
- 1000IU/day of Vitamine D, 5000IU/day of Vitamine D
- Where
- 7 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Chronic Idiopathic Constipation
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).
- Trial name
- NCT01919697
- Testing
- Plecanatide
- Where
- 220 sites in United States, Canada
- Volunteers
- 2,370 people
- Sponsor
- Bausch Health Americas, Inc.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease
- Trial name
- NCT06815003
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.